Deutsche Bank’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$49.5K Buy
+12,652
New +$127K ﹤0.01% 3568
2022
Q2
Sell
-1,349
Closed -$29K 4175
2022
Q1
$29K Sell
1,349
-140
-9% -$3.16K ﹤0.01% 3983
2021
Q4
$43K Buy
1,489
+75
+5% +$3.79K ﹤0.01% 3998
2021
Q3
$138K Buy
1,414
+1,059
+298% +$114K ﹤0.01% 3750
2021
Q2
$46K Sell
355
-11
-3% -$1.59K ﹤0.01% 4323
2021
Q1
$66K Buy
+366
New +$70.6K ﹤0.01% 4163

Other funds holding ELTX

Deutsche Bank's ELTX Position: Q2 2026 in Review

Deutsche Bank opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 12,652 shares worth $49.5K. The stake represents ﹤0.01% of the portfolio and ranks #3568 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in ELTX as recently as Q1 2022.

Deutsche Bank first reported a position in ELTX in Q1 2021 and has held it in 6 quarters since. The position peaked at $138K in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Deutsche Bank held 12,652 shares of Elicio Therapeutics worth $49.5K as of Q2 2026.
  • Elicio Therapeutics was a new Deutsche Bank position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3568 holding.
  • Deutsche Bank first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Deutsche Bank's Elicio Therapeutics position peaked at $138K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.